Breast Cancer associated with carriage of a mutation СНЕК2
The paper presents clinical cases in which the patients were diagnosed with breast cancer (BC) associated with mutations in the CHEK2 gene.Kaprin A.D., Kostin A.A., Styracaceae A. D., Rasskazova E.A., Wide I.M.
Objective. To investigate the characteristics of treatment and prevention in patients with BC associated with СНЕК2 mutation carriage.
Subjects and methods. In 2016-2017, the P.A. Herzen Moscow Oncology Research Institute treated three patients diagnosed with BC associated with CHEK2 mutation carriage. Two cases underwent preventive surgery: prophylactic subcutaneous mastectomy with single-stage reconstruction in one case and prophylactic bilateral tubo-ovariectomy in the other. A further follow-up of these patients and their relatives will be able to draw conclusions about the correctness of preventive surgery policy.
Results. In all the three clinical cases, the patients were diagnosed with germline missense І157Т mutation (p.І1е157Тһr) in exon 3 of the CHEK 2 gene, which results in amino acid substitution (isoleucine to threonine at codon 470 – c.470Т>C) in a heterozygous state. The volume of surgical interventions for BC, preventive surgery on the breast and ovaries in our patients was decided individually based on their clinical data. Genetic examination of their relatives is needed for primary prevention of BC.
Conclusion. There is a need for further investigations in patients with BRCA1, 2, CHEK 2 mutations, as there will be a growing number of patients with mutations in these genes due to a larger number of genetic laboratories. Knowing the characteristics of inheritance and development of hereditary BC, it is necessary to elaborate surgical treatment policy for these patients, algorithms for follow-up of the patients, and an algorithm for examination and prevention of BC among their relatives.
Keywords
breast cancer
gene mutation СНЕК2
hereditary breast cancer
prophylactic mastectomy
References
1. Каприн А.Д., Старинский В.В., Петрова Г.В., ред. Состояние онкологической помощи населению России в 2016 году. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России; 2017. 236с. [Kaprin A.D., Starinskiy V.V., Petrova G.V., ed. Status of oncological care for the population of Russia in 2016. Moscow: MNIOI im. P.A. Gertsena – filial FGBU «NMIRTs» Minzdrava Rossii; 2017. 236p. (in Russian)]
2. Бит-Сава Е.М. Молекулярно-биологическое обоснование лечения BRCA1/СНЕК2/BLM-ассоциированного и спорадического рака молочной железы: дисс. … д-ра мед. наук. СПб.; 2015. [Bit-Sava E.M. Molecular-biological rationale for the treatment of BRCA1 / SNEC2 / BLM-associated and sporadic breast cancer: diss. ... Dr. med. sciences. St. Petersburg; 2015. (in Russian)]
3. Громыко О.Е. Диагностика полиморфизма гена ТПМТ и наследственных мутаций в генах ВRСА1,2 и СНЕК2: автореф. дисс. … канд. мед. наук. М.; 2008. [Gromyiko O.E. Diagnosis of polymorphism of the TPMT gene and hereditary mutations in the genes BRCA1.2 and SNEC2: author’s abstract. diss. ... cand. med. sciences. Moscow; 2008. (in Russian)]
4. Батенева Е.И., Филиппова М.Г., Тюляндина А.С., Мещеряков А.А., Жорданиа К.И., Грицай А.Н., Кадочникова В.В., Абрамов Д.Д., Рагимов А.А., Трофимов Д.Ю., Любченко Л.Н. Высокая частота мутаций в генах BRCA1, BRCA2, CHEK2, NBN, BLM у больных раком яичников в Российской популяции. Опухоли женской репродуктивной системы. 2014; 4: 51-6. [Bateneva E.I., Filippova M.G., Tyulyandina A.S., Mescheryakov A.A., Zhordania K.I., Gritsay A.N., Kadochnikova V.V., Abramov D.D., Ragimov A.A., Trofimov D.Yu., Lyubchenko L.N. High frequency of mutations in the BRCA1, BRCA2, CHEK2, NBN, BLM genes in patients with ovarian cancer in the Russian population. Opuholi zhenskoy reproduktivnoy sistemyi. 2014; 4: 51-6. (in Russian)]
5. Бессонов А.А., Иевлева А.Г., Имянитов Е.Н., Соколенко А.П. Наследственный рак молочной железы, ассоциированный с мутациями в гене СHEK2. Вопросы онкологии. 2016; 62(6): 754-7. [Bessonov A.A., Ievleva A.G., Imyanitov E.N., Sokolenko A.P. Hereditary breast cancer associated with mutations in the gene CHEK2. Voprosyi onkologii. 2016; 62(6): 754-7. (in Russian)]
6. Adank M.A., Jonker M.A., Kluijt I., van Mil S.E., Oldenburg R.A., Mooi W.J. et al. CHEK2* 1100delC homozygosity is associated with breast cancer risk in women. J. Med. Genet. 2011; 48(12): 860-3
7. Cybulski C., Wokołorczyk D., Jakubowska A., Huzarski T., Byrski T., Gronwald J. et al. Risk of breast cancer in women with a' СHEK2 mutation with and without a family history of breast cancer. J. Clin. Oncol. 2011; 29(28): 3747-52.
8. Рагулин Ю.А., Афонин Г.В., Аминов Г.Г., Сидорин А.В. Органосохраняющее лечение первично-диссемированного рака молочной железы с метахронным билатеральным поражением. Опухоли женской репродуктивной системы. 2016; 12(1): 63-7. [Ragulin Yu.A., Afonin G.V., Aminov G.G., Sidorin A.V. Organ-preserving treatment of primary-disseminated breast cancer with metachronous bilateral lesion. Opuholi zhenskoy reproduktivnoy sistemyi. 2016; 12(1): 63-7. (in Russian)]
Received 03.08.2017
Accepted 22.09.2017
About the Authors
Andrei D. Kaprin, corresponding member of the Russian Academy of Sciences, Director of P.A. Herzen Moscow Oncology Research Institute, Branch, National Medical Radiology Research Center, Ministry of Health of Russia. 125284, Russia, Moscow, 2nd Botkinsky proezd, 3. E-mail: Kaprin@yandex.ruAndrey А. Kostin, MD, Deputy Director of P.A. Herzen Moscow Oncology Research Institute, Branch, National Medical Radiology Research Center, Ministry of Health of Russia. 125284, Russia, Moscow, 2nd Botkinsky proezd, 3. E-mail: andocrey@mail.ru
Aziz D. Zikiryakhodzhayev, PhD, MD, Professor of the Department of Oncology and Radiology, Peoples Friendship University of Russia, Head of the Department of Oncology and Reconstructive Surgery of the Mammary Gland and Skin, P.A. Herzen Moscow Oncology Research Institute, Branch, National Medical Radiology Research Center, Ministry of Health of Russia. 125284, Russia, Moscow, 2nd Botkinsky proezd, 3. E-mail: azizz@mail.ru
Elena A. Rasskazova, PhD, researcher of the Department of Oncology and Reconstructive Surgery of the Mammary Gland and Skin, P.A. Herzen Moscow Oncology Research Institute, Branch, National Medical Radiology Research Center, Ministry of Health of Russia. 125284, Russia, Moscow, 2nd Botkinsky proezd, 3. E-mail: Rasskaz2@yandex.ru
Irina M. Shirokikh, post-graduate student of the Department of Oncology and radiology, Peoples’ Friendship University of Russia, Ministry of Education and Science of Russia. 117997, Russia, Moscow, Miklukho-Maklaya str. 8. E-mail: shirokikh-irina1@yandex.ru
For citations: Kaprin A.D., Kostin A.A., Zikiryakhodzhaev A.D., Rasskazova E.A., Shirokikh I.M. Breast cancer associated with СНЕК2 mutation carriage.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2018; (5): 102-7. (in Russian)
https://dx.doi.org/10.18565/aig.2018.5.102-107
Similar Articles
